SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy
- PMID: 15544493
- DOI: 10.2174/1389201043376670
SV40 pseudovirions as highly efficient vectors for gene transfer and their potential application in cancer therapy
Abstract
Among viral and non-viral gene delivery systems, SV40-based vectors show great promise in the cancer gene therapy field. SV40 vectors very efficiently deliver genes such as anti-viral agents, DNA vaccine, genes for chemoprotection (such as ABC transporters genes), suicide genes and antiangiogenic genes. The recombinant SV40 vectors can infect a wide variety of cells-dividing cells as well as non-cycling ones. Most of the SV40-based vectors can incorporate larger transgenes than the capacity of the SV40 wild-type, which is 5.2 kb; Moreover, in vitro packaged vectors demonstrate efficient delivery of plasmids with a molecular weight of up to 17.7 kb. SV40-based vectors carry some SV40 viral sequences, but the SV40 in vitro-packaged vectors are free of any SV40 wild-type viral DNA sequences. These vectors are prepared with nuclear extracts of SF9 insect cells containing the main viral capsid protein of the SV40 wild-type virus, VP1. This review summarizes different strategies in which SV40 vectors are used to deliver genes in vitro, to living mice, and to tumors growing in nude mice.
Similar articles
-
High cloning capacity of in vitro packaged SV40 vectors with no SV40 virus sequences.Hum Gene Ther. 2003 Jan 20;14(2):167-77. doi: 10.1089/104303403321070865. Hum Gene Ther. 2003. PMID: 12614568
-
In vitro assembly of SV40 virions and pseudovirions: vector development for gene therapy.Hum Gene Ther. 1997 May 1;8(7):843-9. doi: 10.1089/hum.1997.8.7-843. Hum Gene Ther. 1997. PMID: 9143910
-
Transduction of multiple cell types using improved conditions for gene delivery and expression of SV40 pseudovirions packaged in vitro.Biotechniques. 2004 Aug;37(2):270-5. doi: 10.2144/04372RR04. Biotechniques. 2004. PMID: 15335219
-
Simian virus-40 as a gene therapy vector.DNA Cell Biol. 2004 May;23(5):271-82. doi: 10.1089/104454904323090903. DNA Cell Biol. 2004. PMID: 15169607 Review.
-
SV40-based gene therapy vectors: turning an adversary into a friend.Curr Opin Mol Ther. 2000 Oct;2(5):570-8. Curr Opin Mol Ther. 2000. PMID: 11249759 Review.
Cited by
-
Causal effects of antibody-mediated immune responses on myocarditis: A two-sample Mendelian randomization study.Medicine (Baltimore). 2025 Jul 18;104(29):e42496. doi: 10.1097/MD.0000000000042496. Medicine (Baltimore). 2025. PMID: 40696586 Free PMC article.
-
DNA-free recombinant SV40 capsids protect mice from acute renal failure by inducing stress response, survival pathway and apoptotic arrest.PLoS One. 2008 Aug 20;3(8):e2998. doi: 10.1371/journal.pone.0002998. PLoS One. 2008. PMID: 18714386 Free PMC article.
-
High cooperativity of the SV40 major capsid protein VP1 in virus assembly.PLoS One. 2007 Aug 22;2(8):e765. doi: 10.1371/journal.pone.0000765. PLoS One. 2007. PMID: 17712413 Free PMC article.
-
SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.Cancer Gene Ther. 2006 Jul;13(7):648-57. doi: 10.1038/sj.cgt.7700943. Epub 2006 Feb 24. Cancer Gene Ther. 2006. PMID: 16498428 Free PMC article.
-
Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions.Hum Gene Ther. 2005 Sep;16(9):1110-5. doi: 10.1089/hum.2005.16.1110. Hum Gene Ther. 2005. PMID: 16149909 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources